Table 1.
PICOS Criteria
| PICOS | Exclusion | |
|---|---|---|
| Patient population | H. pylori positive | |
| Intervention and comparators | FDA-approved regimens for eradication: | • Studies not including at least 2 of the interventions listed in the inclusion criteria |
| PPI-based triple therapies | • Studies evaluating different dosages, durations, and/or sequences (hybrid, sequential, and standard) | |
| • Omeprazole + clarithromycin + amoxicillin or metronidazole | • Non-FDA-approved treatments: Non-bismuth quadruple therapies, LOAD, ranitidine | |
| • Lansoprazole + clarithromycin + amoxicillin or metronidazole | • Non-standard antibiotics: Tinidazole, omidazole, levofloxacin, doxycycline, roxythromycin, moxifloxacin, furazolidone, which are not recommended for use by the ACG guidelines | |
| • Rabeprazole + clarithromycin + amoxicillin or metronidazole | ||
| • Esomeprazole + clarithromycin + amoxicillin or metronidazole | ||
| • Omeprazole + rifabutin + amoxicillin delayed release | ||
| Bismuth therapies | ||
| • Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride | ||
| • Bismuth subsalicylate, metronidazole, tetracycline hydrochloride | ||
| Other | ||
| • High-dose amoxicillin dual | ||
| Outcomes measures | • First-line H. pylori eradication rate | • Studies not including the outcomes listed in the inclusion criteria |
| Study design | • Randomized clinical trials (including extension studies) | • Non-human/pre-clinical studies |
| • Systematic reviews and meta-analyses (for cross-checking only) | • Single arm and non-randomized or un-controlled studies | |
| • Non-interventional studies | ||
| • Retrospective studies | ||
| • Observational studies | ||
| • Case reports/series | ||
| Restrictions | • English language | • Non-English language studies |
| • Year limit: None | Abstract only | |
ACG, American College of Gastroenterology; FDA, Food and Drug Administration; PPI, proton pump inhibitor.